Class: PharmaceuticalProduct
Qualitative and quantitative composition of a medicinal product in the dose form authorized by the regulatory authority for administration to patients, and as represented with any corresponding regulated product information. NOTE: A medicinal product may contain one or more pharmaceutical products. In many instances, the pharmaceutical product is the manufactured item. However, there are instances where the manufactured item undergoes further preparation before being administered to the patient (as the pharmaceutical product). https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C42639
Alternative Descriptions
* IDMPO | |
Aliases
* Product
Examples
| Value | Description
| --- | --- |
| [Ventolin HFA](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020983) | Ventolin HFA is a bronchodilator used to treat or prevent bronchospasm in individuals with asthma or chronic obstructive pulmonary disease (COPD). |
Annotations
| property | value |
| --- | --- |
| definition_source | https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C42639 |
| definition_source_attribution | NCI-Thesaurus (NCIT) |
| definition_source_licence | [CC-BY-4.0](https://creativecommons.org/licenses/by/4.0/) |
| definition_access_date | 2025-05-30 |
| expert_approval_date | 2025-06-12 |
| conceptual_clarification | * OMG Product Term-- The IDMP Ontology (IDMP-O) builds on the OMG definition of 'Product,' with specific refinements such as 'pharmaceutical product' and 'medicinal product.' It distinguishes between physical instances (e.g., 'physical pharmaceutical product') and specification-level abstractions. The IDMP-O terms are currently reused in ClinOps for regulatory and clinical operations purposes.
* NCIT C42639-- Sourced from CDISC and based on ISO 11615--2017 (3.1.60), this definition is widely accepted but may exclude non-medicinal or device-inclusive scenarios. Stakeholders noted this as the most promising candidate, though its current scope may require supplementation.
* IDMP Medicinal Product-- Also considered a robust definition, but viewed as potentially too narrow for inclusion of certain use cases such as combination products or non-drug entities. |
Comments
* The meeting aimed to evaluate and refine the conceptual and semantic alignment of the term 'Product'. This discussion was framed by the need for clarity and specificity in labeling within the PGO and broader terminology models used across the pharmaceutical and biomedical domains. Several alignment meetings related to the core concepts 'compound', 'substance' and 'drug' also had elements related to this discussion.
* Source Definitions Considered included -- * OMG Product Term-- The IDMP Ontology (IDMP-O) builds on the OMG definition of 'Product,' with specific refinements such as 'pharmaceutical product' and 'medicinal product.' It distinguishes between physical instances (e.g., 'physical pharmaceutical product') and specification-level abstractions. The IDMP-O terms are currently reused in ClinOps for regulatory and clinical operations purposes.* NCIT C42639-- Sourced from CDISC and based on ISO 11615--2017 (3.1.60), this definition is widely accepted but may exclude non-medicinal or device-inclusive scenarios. Stakeholders noted this as the most promising candidate, though its current scope may require supplementation.* IDMP Medicinal Product-- Also considered a robust definition, but viewed as potentially too narrow for inclusion of certain use cases such as combination products or non-drug entities.
* Meeting notes - The expert address the PGO Steering Committee recommendations (Cambridge, UK, March 2025) to provide clarity and granularity as to the concept of' product', which is rather generic. - There was broad consensus that a more precise label such as 'Pharmaceutical_Product' is preferred over the generic term 'Product' to reduce semantic ambiguity, particularly for use in early R&D, regulatory documentation, and CMC (Chemistry, Manufacturing, and Controls) processes. - It was discussed whether medical devices—especially those integrated with drugs (e.g., inhalers, EpiPens)—should fall within the 'Product' concept and actually help to clarify it. IDMP-O, being designed for medicinal products, currently does not encompass such hybrid or device-only entities. IDMP-O definitions overlap with 'substance'.- The CDISC-derived NCIT definition was identified as suitable for most PGO use cases. However, digital therapeutics, implanted mechanical devices, and companion diagnostics are not covered by any of the current definitions and may require a broader core concept or an additional ontology term to address their commercial and functional relevance. A need was identified to recognize the commercial aspect of 'product,' which includes digital solutions and other non-pharmaceutical items marketed by life science companies.
* Recommendations to the PGO steering group 1. Adopt as a label--' Pharmaceutical_Product' instead of 'Product'2. Adopt as the NCIT_C42639/CDISC/ISO 11615 Definition of Pharmaceutical_Product'Qualitative and quantitative composition of a medicinal product in the dose form authorized by the regulatory authority for administration to patients, and as represented with any corresponding regulated product information.' NOTE-- A medicinal product may contain one or more pharmaceutical products. In many instances, the pharmaceutical product is the manufactured item. However, there are instances where the manufactured item undergoes further preparation before being administered to the patient (as the pharmaceutical product).' 3. However, digital therapeutics, implanted mechanical devices, and companion diagnostics are not covered by any of the current definitions and may require a broader core concept or an additional ontology term to address their commercial and functional relevance."
TODOs
## TODOs
* Review preferred sources